Table A13.
Example application of HPV-FRAME guidelines to Jit et al., 2015 [114].
| Inputs | Reported? (Y/N) | Report by Age? (Y/N) | Report by sex? (B, F, M) | Comments |
|---|---|---|---|---|
| Vaccine efficacy/waning (by dose, type) | Y | Y (implicitly) | N/A | Full protection against 16/18 (2- and 3-dose) Waning: 10, 20 or 30 years for 2-dose with exponential or uniform waning functions Age dependency: 2-dose regime only given to 12-year olds in modelled scenarios. |
| Timing between doses (for 2-dose) | Y | N/A | N/A | 2-dose regime only given to 12-year olds in modelled scenarios. |
| Vaccine cross-protection (by dose, type) | Y | Y (implicitly) | N/A | Partial efficacy against 31/33/45/52/58 assumed for 2- and 3-dose; sensitivity analysis with no cross-protection for 2-dose |
| Cost per dose/per vaccinated individual |
Y |
N |
N/A |
Cost per dose assumed constant |
| Output |
Reported? (Y/N) |
Report by Age? (Y/N) |
Report by sex? (B, F, M) |
Report as calibration or validation target? (Y/N) |
| Threshold cost per dose | N | N | N |
B: both sexes, F: female only; M: male only; N: no; Y: yes.